China has reportedly taken a significant lead over Elon Musk’s Neuralink by successfully conducting the world’s first commercial implantation of a brain-computer interface (BCI). This operation occurred at Huashan Hospital, affiliated with Fudan University in Shanghai, involving a patient with a spinal cord injury. The device used in the surgery has received regulatory approval, marking a transition from experimental trials to practical medical application.

The patient, who suffered a spinal cord injury from a car accident approximately ten years ago, had been unable to effectively use their hands despite receiving extensive rehabilitation. Following a thorough evaluation by a multidisciplinary team of medical professionals, the individual was chosen for the procedure, which utilised the Neural Electronic Opportunity (NEO) system developed by Shanghai’s Neuracle Medical Technology.

According to reports, the patient’s condition was stable post-surgery, with tests indicating that the device adeptly captured high-quality brain signals throughout the procedure. This advancement signifies a notable progression in BCI technology, offering potential new avenues for recovery in individuals with similar conditions.

Understanding the Neo System

The NEO system functions by interpreting brain signals and converting them into commands for external devices. Unlike traditional implants, this coin-sized device is placed on the brain’s surface without penetrating the tissue, making the approach less invasive. When the patient contemplates moving their hand, the implant detects these brain signals and transmits them to a computer, which translates them into commands that can control a robotic glove.

The primary objective of the NEO system is to assist individuals with paralysis in regaining hand movement and performing daily tasks independently. This is a significant enhancement in the functionality of assistive devices, promoting increased autonomy for users who have previously faced limitations.

Earlier this year, in March, China’s National Medical Products Administration granted commercial approval for the NEO system, designating it as the first implantable brain-computer interface classified as a Class III medical device. This regulatory milestone allows for the technology to advance beyond experimental statuses and into routine medical treatments across hospitals for eligible patients.

Comparison Between Neo and Neuralink

Elon Musk’s Neuralink is also developing similar brain-computer interface technology and has initiated clinical trials in the United States. Its initial product, known as Telepathy, is designed to enable individuals with paralysis to operate computers and smartphones solely with their thoughts. However, while Neuralink has achieved some implantations, these procedures remain within the framework of clinical research.

The NEO system’s commercial approval allows immediate practical use in clinical settings in China, contrasting with Neuralink, which is still awaiting comprehensive approval from the US Food and Drug Administration (FDA) for its technology. This difference highlights the regulatory landscape surrounding medical devices in various countries and the timeline discrepancies in commercial readiness.

Moreover, the two systems employ differing methodologies in their implantation techniques. Neuralink’s device utilises ultra-thin, flexible threads that are inserted into the brain tissue through robotic assistance. In comparison, the Neo system’s non-invasive method of placement on the brain’s surface presents a less intrusive alternative while still effectively retrieving the brain signals necessary for controlling assistive technology.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share